• Profile
Close

A phase 2 randomized trial of apremilast in patients with atopic dermatitis

Journal of Investigative Dermatology Dec 10, 2018

Simpson E, et al. - Experts conducted a phase 2, double-blind, placebo-controlled trial to assess the apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). They randomized the patients to placebo, apremilast 30 mg BID (APR30), or apremilast 40 mg BID (APR40) for 12 weeks. In moderate to severe AD patients, modest efficacy and decreased AD-related biomarkers was demonstrated by APR40. They noted adverse events (AEs), including cellulitis, more frequently with APR40, which was discontinued during the trial. With apremilast’s known profile, safety with APR30 was largely consistent.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay